BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.
Video navigation menu
- Unmet needs in the management of diabetes and CKD may be met by novel epigenetic therapies that alter transcription of several genes simultaneously. 0:30
- BET inhibition with apabetalone reduces calcification in in vitro models, likely by downregulation of alkaline phosphatase (ALP) expression 3:31
- ALP has been linked to mortality, CV disease and diabetes, especially in CKD patients 6:48
- SInce ALP emerges as an important prognostic biomarker of CV events, can it be lowered in vivo, aiming to reduce events? 11:54
- Hypothetical model based on in vitro and in vivo data of how BET inhibition may lower ALP expression with potential CV benefit 17:16
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA
This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.
The symposium was supported by an unrestricted educational grant from Resverlogix Corp